Barclays
NRIX icon

Barclays’s Nurix Therapeutics NRIX Stock Holding History

Barclays’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$375K Sell
24,180
-232,504
-91% -$3.86M ﹤0.01% 3348
2025
Q4 		$4.87M Buy
256,684
+11,589
+5% +$166K ﹤0.01% 2240
2025
Q3 		$2.26M Sell
245,095
-9,775
-4% -$102K ﹤0.01% 2803
2025
Q2 		$2.9M Buy
254,870
+110,095
+76% +$1.19M ﹤0.01% 2557
2025
Q1 		$1.72M Sell
144,775
-4,561
-3% -$76.3K ﹤0.01% 2734
2024
Q4 		$2.81M Buy
149,336
+20,992
+16% +$481K ﹤0.01% 2644
2024
Q3 		$2.88M Buy
128,344
+56,190
+78% +$1.27M ﹤0.01% 2547
2024
Q2 		$1.51M Buy
72,154
+24,639
+52% +$384K ﹤0.01% 2338
2024
Q1 		$698K Sell
47,515
-21,224
-31% -$228K ﹤0.01% 3374
2023
Q4 		$709K Buy
68,739
+1,272
+2% +$8.72K ﹤0.01% 3669
2023
Q3 		$530K Sell
67,467
-1,524
-2% -$13.9K ﹤0.01% 2770
2023
Q2 		$689K Sell
68,991
-3,156
-4% -$32.2K ﹤0.01% 2556
2023
Q1 		$641K Sell
72,147
-27,510
-28% -$287K ﹤0.01% 3085
2022
Q4 		$1.09M Buy
99,657
+15,166
+18% +$183K ﹤0.01% 2715
2022
Q3 		$1.1M Buy
84,491
+81,760
+2,994% +$1.29M ﹤0.01% 2163
2022
Q2 		$34K Sell
2,731
-2,448
-47% -$27.7K ﹤0.01% 4195
2022
Q1 		$72K Buy
+5,179
New +$91.9K ﹤0.01% 3940

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Barclays's NRIX Position: Q1 2026 in Review

Barclays reduced its Nurix Therapeutics (NRIX) stake by 91% in Q1 2026, selling an estimated $3.86M and leaving 24,180 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #3348.

Barclays first reported a position in NRIX in Q1 2022 and has held it in 17 quarters since. The position peaked at $4.87M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Barclays held 24,180 shares of Nurix Therapeutics worth $375K as of Q1 2026.
  • Barclays sold 232,504 Nurix Therapeutics shares in Q1 2026, an estimated $3.86M.
  • Nurix Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3348 holding.
  • Barclays first reported a position in Nurix Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Nurix Therapeutics position peaked at $4.87M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.